title: Cancer vaccines: moving toward prevention?
abstract: After several decades of research, recent successful phase III controlled clinical trials have renewed enthusiasm for vaccine treatment of cancer. This perspective on the report by Berta and colleagues in this issue of the journal (beginning on page 994) discusses the potential prevention of oral cancer through vaccine strategies and, in the broader context, ideal characteristics of tumor antigens as candidates for vaccines for both treating and preventing cancer, potential primary and secondary prevention settings for vaccines, desirable types of immune effectors induced by vaccines, and safety.
authors: Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 429, Houston, TX 77030, USA. lkwak@mdanderson.org
authors: Larry W
authors: LW
authors: Kwak
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene / Q000633:toxicity*; D000818:Animals; D002273:Carcinogens / Q000633:toxicity*; D002294:Carcinoma, Squamous Cell / Q000517:prevention & control*; D008297:Male; D009062:Mouth Neoplasms / Q000517:prevention & control*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D019444:Vaccines, DNA / Q000627:therapeutic use*
chemical_list: D015127:9,10-Dimethyl-1,2-benzanthracene; D002273:Carcinogens; D018719:Erb-b2 Receptor Tyrosine Kinases; D019444:Vaccines, DNA